Get the Stockscreener App
1.30
2.36%
+0.03
Femasys Inc stock is currently priced at $1.30, with a 24-hour trading volume of 108.40K.
It has seen a +2.36% increased in the last 24 hours and a -24.42% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.29 pivot point. If it approaches the $1.31 resistance level, significant changes may occur.
Previous Close:
$1.27
Open:
$1.27
24h Volume:
108.40K
Market Cap:
$28.73M
Revenue:
$1.07M
Net Income/Loss:
$-14.25M
P/E Ratio:
-1.3542
EPS:
-0.96
Net Cash Flow:
$-11.42M
1W Performance:
-2.26%
1M Performance:
-24.42%
6M Performance:
-6.47%
1Y Performance:
+40.85%
1D Range:
$1.27
$1.34
52W Range:
$0.2479
$4.75
Femasys Inc Stock (FEMY) Company Profile
Name
Femasys Inc
Sector
Industry
Phone
770 500 3910
Address
3950 Johns Creek Court, Suite 100, Suwanee
Femasys Inc Stock (FEMY) Latest News
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
GlobeNewswire Inc.
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
GlobeNewswire Inc.
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
GlobeNewswire Inc.
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
GlobeNewswire Inc.
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
GlobeNewswire Inc.
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
GlobeNewswire Inc.
Femasys Inc Stock (FEMY) Financials Data
Femasys Inc (FEMY) Revenue 2024
FEMY reported a revenue (TTM) of $1.07 million for the quarter ending December 31, 2023, a -11.13% decline year-over-year.
Femasys Inc (FEMY) Net Income 2024
FEMY net income (TTM) was -$14.25 million for the quarter ending December 31, 2023, a -25.04% decrease year-over-year.
Femasys Inc (FEMY) Cash Flow 2024
FEMY recorded a free cash flow (TTM) of -$11.42 million for the quarter ending December 31, 2023, a -2.56% decrease year-over-year.
Femasys Inc (FEMY) Earnings per Share 2024
FEMY earnings per share (TTM) was -$0.92 for the quarter ending December 31, 2023, a +3.16% growth year-over-year.
About Femasys Inc
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
0.69%
0.07%
Cap:
|
Volume (24h):